Insider transactions

EDGAR

MAIA Biotechnology, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
30 transactions, 866,200 shares
Sum of shares × price per share: 1,075,877.189
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 63

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-30 Filed 2026-10-02Guerrero Ramiro Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (32,012) — exercise price 1.18
Acquired (A)32,0120—32,012Direct (D) No
F1
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000096 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Luput Cristian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (33,536) — exercise price 1.18
Acquired (A)33,5360—33,536Direct (D) No
F1
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000098 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Smith Stan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (38,871) — exercise price 1.18
Acquired (A)38,8710—38,871Indirect (I) See footnoteNo
F1, F2
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-26-000099 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02CHAOUKI STEVEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (32,774) — exercise price 1.18
Acquired (A)32,7740—32,774Direct (D) No
F1
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000095 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Louie Ngar Yee Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (39,634) — exercise price 1.18
Acquired (A)39,6340—39,634Direct (D) No
F1
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000097 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Theagene Jean-Manasse Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (32,012) — exercise price 1.18
Acquired (A)32,0120—32,012Direct (D) No
F1
  • F1 The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000100 Read from the filing’s XML Dispute this row
2026-09-14 Filed 2026-09-15Vitoc Vlad Director · Officer: Chief Executive Officer · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)73,0001.37
100,010

Derived: shares × price per share. Exact value 100010.00.

1,049,121Direct (D) No— Open filing 0001878313-26-000087 Read from the filing’s XML Dispute this row
2026-09-10 Filed 2026-09-14Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)37,5951.3171
49,516.3745

Derived: shares × price per share. Exact value 49516.3745.

773,296Direct (D) No— Open filing 0001878313-26-000084 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-09-01Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)46,6201.35
62,937

Derived: shares × price per share. Exact value 62937.00.

735,701Direct (D) No— Open filing 0001878313-26-000082 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-09-01Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)78,2391.39
108,752.21

Derived: shares × price per share. Exact value 108752.21.

689,081Direct (D) No— Open filing 0001878313-26-000082 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-09-01Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)8,9311.39
12,414.09

Derived: shares × price per share. Exact value 12414.09.

610,842Direct (D) No— Open filing 0001878313-26-000082 Read from the filing’s XML Dispute this row
2026-08-24 Filed 2026-08-26Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,7941.33
2,386.02

Derived: shares × price per share. Exact value 2386.02.

601,911Direct (D) No— Open filing 0001878313-26-000079 Read from the filing’s XML Dispute this row
2026-08-20 Filed 2026-08-24Guerrero Ramiro Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)11,8991.37
16,301.63

Derived: shares × price per share. Exact value 16301.63.

600,117Direct (D) No— Open filing 0001878313-26-000077 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Louie Ngar Yee Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (32,630) — exercise price 1.44
Acquired (A)32,6300—32,630Direct (D) No
F1
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000072 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Guerrero Ramiro Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (26,355) — exercise price 1.44
Acquired (A)26,3550—26,355Direct (D) No
F1
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000073 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Theagene Jean-Manasse Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (26,355) — exercise price 1.44
Acquired (A)26,3550—26,355Direct (D) No
F1
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000069 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Luput Cristian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (27,610) — exercise price 1.44
Acquired (A)27,6100—27,610Direct (D) No
F1
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000071 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02CHAOUKI STEVEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (26,982) — exercise price 1.44
Acquired (A)26,9820—26,982Direct (D) No
F1
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000074 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Smith Stan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (32,003) — exercise price 1.44
Acquired (A)32,0030—32,003Indirect (I) See footnoteNo
F1, F2
  • F1 The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-26-000070 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Vitoc Vlad Director · Officer: Chief Executive Officer · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)72,7001.3877
100,885.79

Derived: shares × price per share. Exact value 100885.7900.

976,121Direct (D) No
F1
  • F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.3634 to $1.4150, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Open filing 0001878313-26-000062 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)75,0001.336
100,200

Derived: shares × price per share. Exact value 100200.000.

1,519,178Indirect (I) See FootnoteNo
F1, F2
  • F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.32 to $1.40, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-26-000061 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Gryaznov Sergei Officer: Chief Scientific Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,0001.345
2,690

Derived: shares × price per share. Exact value 2690.000.

46,511Direct (D) No— Open filing 0001878313-26-000060 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-01Gryaznov Sergei Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (400,000) — exercise price 1.39
Acquired (A)400,0000—400,000Direct (D) No
F1
  • F1 The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000051 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-01Vitoc Vlad Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (800,000) — exercise price 1.39
Acquired (A)800,0000—800,000Direct (D) No
F1
  • F1 The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000053 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-01Himmelreich Jeffrey C Officer: Head of Finance
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (60,000) — exercise price 1.39
Acquired (A)60,0000—60,000Direct (D) No
F1
  • F1 The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000049 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-14Vitoc Vlad Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (800,000) — exercise price 1.28
Acquired (A)800,0000—800,000Direct (D) No
F1
  • F1 The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000047 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-14Gryaznov Sergei Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (400,000) — exercise price 1.28
Acquired (A)400,0000—400,000Direct (D) No
F1
  • F1 The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000046 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-14Himmelreich Jeffrey C Officer: Head of Finance
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (30,000) — exercise price 1.28
Acquired (A)30,0000—30,000Direct (D) No
F1
  • F1 The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Open filing 0001878313-26-000044 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Luput Cristian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (28,556) — exercise price 1.40
Acquired (A)28,5560—28,556Direct (D) No
F1
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000033 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Smith Stan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (33,099) — exercise price 1.40
Acquired (A)33,0990—33,099Indirect (I) See footnoteNo
F1, F2
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-26-000029 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Guerrero Ramiro Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (27,258) — exercise price 1.40
Acquired (A)27,2580—27,258Direct (D) No
F1
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000037 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02CHAOUKI STEVEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (27,907) — exercise price 1.40
Acquired (A)27,9070—27,907Direct (D) No
F1
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000039 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Theagene Jean-Manasse Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (27,258) — exercise price 1.40
Acquired (A)27,2580—27,258Direct (D) No
F1
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000031 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Louie Ngar Yee Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (33,748) — exercise price 1.40
Acquired (A)33,7480—33,748Direct (D) No
F1
  • F1 The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000035 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05CHAOUKI STEVEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (24,633) — exercise price 1.53
Acquired (A)24,6330—24,633Direct (D) No
F1
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000008 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Theagene Jean-Manasse Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (24,060) — exercise price 1.53
Acquired (A)24,0600—24,060Direct (D) No
F1
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000018 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Smith Stan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (29,216) — exercise price 1.53
Acquired (A)29,2160—29,216Indirect (I) See footnoteNo
F1, F2
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-26-000016 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Guerrero Ramiro Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (24,060) — exercise price 1.53
Acquired (A)24,0600—24,060Direct (D) No
F1
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000010 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Louie Ngar Yee Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (29,789) — exercise price 1.53
Acquired (A)29,7890—29,789Direct (D) No
F1
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000012 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-05Luput Cristian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Options — underlying Common Stock (25,206) — exercise price 1.53
Acquired (A)25,2060—25,206Direct (D) No
F1
  • F1 The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Open filing 0001878313-26-000014 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23Louie Ngar Yee Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)81,6991.224
99,999.576

Derived: shares × price per share. Exact value 99999.576.

1,248,888Direct (D) No
F1
  • F1 The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025
Open filing 0001878313-25-000069 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23Louie Ngar Yee Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Stock Options — underlying Common Stock (81,699) — exercise price 1.36
Acquired (A)81,6991.36
111,110.64

Derived: shares × price per share. Exact value 111110.64.

81,699Direct (D) No
F2
  • F2 These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.
Open filing 0001878313-25-000069 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23CHAOUKI STEVEN M Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)40,8491.224
49,999.176

Derived: shares × price per share. Exact value 49999.176.

151,873Direct (D) No
F1
  • F1 The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.
Open filing 0001878313-25-000071 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23CHAOUKI STEVEN M Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Stock Options — underlying Common Stock (40,849) — exercise price 1.36
Acquired (A)40,8491.36
55,554.64

Derived: shares × price per share. Exact value 55554.64.

40,849Direct (D) No
F2
  • F2 These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.
Open filing 0001878313-25-000071 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)57,1891.224
69,999.336

Derived: shares × price per share. Exact value 69999.336.

1,421,478Indirect (I) See FootnoteNo
F1, F2
  • F1 The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.
  • F2 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-25-000073 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-23Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Stock Options — underlying Common Stock (57,189) — exercise price 1.36
Acquired (A)57,1891.36
77,777.04

Derived: shares × price per share. Exact value 77777.04.

57,189Indirect (I) See footnoteNo
F6, F7
  • F6 These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the sixth month anniversary of the issuance date and expire 3-years after the initial issuance date.
  • F7 These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Open filing 0001878313-25-000073 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)4,5801.1997
5,494.626

Derived: shares × price per share. Exact value 5494.6260.

4,580Indirect (I) See footnoteNo
F1
  • F1 These securities are beneficially owned by Mr. Smith through the Travis Deo Zai Zai Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Open filing 0001878313-25-000063 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)4,5801.19
5,450.2

Derived: shares × price per share. Exact value 5450.20.

4,580Indirect (I) See footnoteNo
F2
  • F2 These securities are beneficially owned by Mr. Smith through the Gage Quentin Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Open filing 0001878313-25-000063 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Smith Stan Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)4,5801.20
5,496

Derived: shares × price per share. Exact value 5496.00.

4,580Indirect (I) See footnoteNo
F3
  • F3 These securities are beneficially owned by Mr. Smith through the Blake Sarai Teitei Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Open filing 0001878313-25-000063 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-04Vitoc Vlad Director · Officer: Chief Executive Officer · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)50,0001.1366
56,830

Derived: shares × price per share. Exact value 56830.0000.

903,421Direct (D) No
F2, F3
  • F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  • F3 The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Vlad Vitoc. This Amended Form 4 is now reflecting the correct share balance owned.
Open filing 0001878313-25-000059 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–44 of 44

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Solas Capital Management, LLC 3,030,845 SH3,576,397 dollarsUnchanged Prior quarter: 3,030,845Open filing 0001604867-26-000022 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,413,270 SH2,847,659 dollarsUnchanged Prior quarter: 2,413,270Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Centric Wealth Management 1,167,070 SH1,272,106 dollarsHigher by 370,347 Prior quarter: 796,723Open filing 0001104659-26-125733 Filed 2026-11-12 Dispute this row
683 Capital Management, LLC Partly reported under another manager1,066,666 SH1,258,666 dollarsUnchanged Prior quarter: 1,066,666Open filing 0001404574-26-000027 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager584,401 SH689,808 dollarsHigher by 80,021 Prior quarter: 504,380Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Cable Car Capital, LP 514,583 SH607,208 dollarsUnchanged Prior quarter: 514,583Open filing 0001699575-26-000008 Filed 2026-11-16 Dispute this row
Bleichroeder LP 500,000 SH590,000 dollarsUnchanged Prior quarter: 500,000Open filing 0001420506-26-002662 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager399,100 SH470,938 dollarsLower by 16,600 Prior quarter: 415,700Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
BlackRock, Inc. Partly reported under another manager394,772 SH465,830 dollarsLower by 8,239 Prior quarter: 403,011Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 336,688 SH397,292 dollarsUnchanged Prior quarter: 336,688Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Alyeska Investment Group, L.P. 295,436 SH348,614 dollarsLower by 2,204,564 Prior quarter: 2,500,000Open filing 0001172661-26-005329 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager226,877 SH267,715 dollarsHigher by 201,987 Prior quarter: 24,890Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager218,850 SH258,243 dollarsHigher by 17,100 Prior quarter: 201,750Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Bleakley Financial Group, LLC 181,623 SH214,315 dollarsUnchanged Prior quarter: 181,623Open filing 0001936953-26-000005 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager125,171 SH147,702 dollarsUnchanged Prior quarter: 125,171Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager104,017 SH122,740 dollarsUnchanged Prior quarter: 104,017Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager84,774 SH100,033 dollarsNot in the prior quarter’s filings read Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
Empowered Funds, LLC Partly reported under another manager74,757 SH88,213 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 74,757 SH88,213 dollarsLower by 1,243 Prior quarter: 76,000Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
StoneX Group Inc. Partly reported under another manager60,151 SH77,672 dollarsNot in the prior quarter’s filings read Open filing 0000913760-26-000042 Filed 2026-11-03 Dispute this row
ENVESTNET ASSET MANAGEMENT INC 40,150 SH47,377 dollarsLower by 4,197 Prior quarter: 44,347Open filing 0001214659-26-014231 Filed 2026-11-16 Dispute this row
Quadrature Capital Ltd Partly reported under another manager37,840 SH44,651 dollarsNot in the prior quarter’s filings read Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
PVG ASSET MANAGEMENT CORP Partly reported under another manager34,135 SH40,279 dollarsUnchanged Prior quarter: 34,135Open filing 0000820434-26-000009 Filed 2026-10-19 Dispute this row
Spark Investment Management LLC 25,400 SH29,972 dollarsNot in the prior quarter’s filings read Open filing 0000899140-26-001312 Filed 2026-11-13 Dispute this row
LAZARI CAPITAL MANAGEMENT, INC. 21,750 SH25,665 dollarsUnchanged Prior quarter: 21,750Open filing 0001986389-26-000007 Filed 2026-10-20 Dispute this row
Atria Investments, Inc 20,754 SH24,490 dollarsLower by 346 Prior quarter: 21,100Open filing 0001535865-26-000012 Filed 2026-10-15 Dispute this row
Cetera Investment Advisers 18,669 SH22,029 dollarsLower by 4,079 Prior quarter: 22,748Open filing 0001666741-26-000005 Filed 2026-11-13 Dispute this row
Point72 Asset Management, L.P. 17,175 SH20,267 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
Centerpoint Advisory Group 15,730 SH18,561 dollarsUnchanged Prior quarter: 15,730Open filing 0002085853-26-001285 Filed 2026-10-23 Dispute this row
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 14,800 SH17,020 dollarsUnchanged Prior quarter: 14,800Open filing 0001214659-26-012804 Filed 2026-10-13 Dispute this row
TWO SIGMA INVESTMENTS, LP 13,917 SH16,422 dollarsLower by 36,466 Prior quarter: 50,383Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Vanguard Global Advisers, LLC 11,401 SH13,453 dollarsUnchanged Prior quarter: 11,401Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager8,334 SH9,834 dollarsUnchanged Prior quarter: 8,334Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Daytona Street Capital LLC 7,500 SH8,925 dollarsUnchanged Prior quarter: 7,500Open filing 0002101936-26-000004 Filed 2026-10-15 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager5,312 SH6,268 dollarsHigher by 2,104 Prior quarter: 3,208Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Nuveen, LLC Partly reported under another manager2,357 SH2,711 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
CITIGROUP INC Partly reported under another manager1,831 SH2,161 dollarsHigher by 1,681 Prior quarter: 150Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager823 SH1,000 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
Strategic Investment Solutions, Inc. /IL 300 SH354 dollarsNot in the prior quarter’s filings read Open filing 0001062993-26-005940 Filed 2026-11-12 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager228 SH274 dollarsUnchanged Prior quarter: 228Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager200 SH236 dollarsUnchanged Prior quarter: 200Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
Caitong International Asset Management Co., Ltd 177 SH209 dollarsLower by 33 Prior quarter: 210Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager23 SH26 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
BARCLAYS PLC Partly reported under another manager3 SH4 dollarsLower by 4,149 Prior quarter: 4,152Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 35,223 SH
  • UBS Group AG 33,435 SH
  • MERCER GLOBAL ADVISORS INC /ADV 455 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Solas Capital Management, LLC Common Stock, $0.0001 par value per share4.93,030,845.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001604867-26-000014 Dispute this row
FREDERICK TUCKER GOLDEN Common Stock, $0.0001 par value per share4.93,030,845.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001604867-26-000014 Dispute this row
Solas Capital Management, LLC Common Stock, $0.0001 par value per share7.14,297,004.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001604867-26-000011 Dispute this row
FREDERICK TUCKER GOLDEN Common Stock, $0.0001 par value per share7.14,297,004.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001604867-26-000011 Dispute this row
Vlad Vitoc Common Stock, $0.0001 par value9.663,846,352.0011/21/2025 Filed 2025-12-04SCHEDULE 13D/AAmendment 1Open filing 0001493152-25-026173 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,462,728 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,836
2016222,374
2017207,870
2018222,268
2019215,153
2020166,955
2021249,834
2022187,707
2023229,670
2024219,215
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to MAIA Biotechnology, Inc.